Melanie K. Kuester

We review drugs awaiting approval that have the potential to change current treatment paradigms, displace current therapies, or create new spending categories.

This paper quantifies healthcare utilization metrics for individuals using obesity-related treatments and explores the impact of obesity management from an employer viewpoint.

This study, commissioned by Eli Lilly, describes the retention of employees with and without diagnosed obesity who are employed by self-insured employers.

Gene therapies for sickle cell disease show promise, but broad access requires more collaboration among manufacturers, payers, and healthcare systems.

This study sought to determine whether a relationship between obesity and employee retention exists, providing insights into the duration that employees with obesity remain with their employers.

From manufacturer rebates to risk corridors, Milliman pharmacy experts discuss strategies for paying for high-cost drugs.

How might requiring Part D coverage for anti-obesity medications affect Medicare program costs?

As drug costs continue to rise, states need to engage in strategies that include policy and nonpolicy options to manage prescription spending in Medicaid.

Regenerative and targeted therapies increase the need to accurately identify rare diseases, and increased specificity in diagnosis codes of the ICD-10 could help

This paper discusses several decision points and considerations for states evaluating a single preferred drug list requirement.